Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Common Equity (2019 - 2025)

BioScience Health Innovations (BHIC) has disclosed Common Equity for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 76.87% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 76.87% year-over-year, with the annual reading at $1.5 million for FY2025, 76.87% up from the prior year.
  • Common Equity for Q4 2025 was $1.5 million at BioScience Health Innovations, down from $1.7 million in the prior quarter.
  • The five-year high for Common Equity was $1.7 million in Q2 2025, with the low at -$88990.0 in Q1 2023.
  • Average Common Equity over 5 years is $384378.2, with a median of $40534.0 recorded in 2022.
  • The sharpest move saw Common Equity crashed 20776.92% in 2021, then surged 12455.62% in 2024.
  • Over 5 years, Common Equity stood at $73119.0 in 2021, then crashed by 65.16% to $25476.0 in 2022, then tumbled by 126.53% to -$6760.0 in 2023, then soared by 12455.62% to $835240.0 in 2024, then soared by 76.87% to $1.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $1.5 million, $1.7 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.